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Abstract BACKGROUND CONTEXT: The efficacy and safety of recombinant human bone morphoge-
netic protein-2 (rhBMP-2) as a bone graft substitute in spinal fusion has been widely researched.
However, no study of the efficacy and safety of Escherichia coli-derived rhBMP-2 (E.BMP-2) with
a hydroxyapatite (HA) carrier has been proposed.
PURPOSE: This study aimed to compare the efficacy and safety of fusion materials between E.BMP-2
and autogenous iliac bone graft in posterolateral fusion (PLF).
STUDY DESIGN/SETTING: An open, active-controlled, randomized, multicenter trial was carried
out.
PATIENT SAMPLE: This study included 93 patients who underwent single-level lumbar or lum-
bosacral PLF.
OUTCOME MEASURES: The primary outcome measure was computed tomography (CT)-
based fusion rate at 12 and 24 weeks. Secondary outcome measures were fusion grade by radiographs
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and CT at 12 and 24 weeks and changes in Oswestry Disability Index (ODI), Short Form-36 (SF-36)
Health Survey, and visual analogue scale (VAS).
METHODS: Patients who underwent 1-level PLF (between L1 and S1) for severe spinal stenosis
or grade 1 spondylolisthesis were randomized to receive E.BMP-2 with an HA carrier (E.BMP-2
group) or autogenous iliac bone graft (AIBG group). Thin-section CT (<2 mm), VAS, ODI, and SF-
36 were obtained pre- and postoperatively at 12 and 24 weeks. Outcome measures were compared
between the groups.
RESULTS: A total of 100 patients were enrolled in this trial. Among them, 93 patients underwent
planned surgery. Preoperative demographic and clinical data showed no difference between groups.
CT-based fusion rates were 100.0% (41/41) for the E.BMP-2 group and 90.2% (46/51) for the AIBG
group (p=.062) at 12 weeks and 100.0% (41/41) and 94.1% (48/51) (p=.251) at 24 weeks, respec-
tively. Fusion grade based on radiographs and CT showed non-inferiority of the E.BMP-2 group
compared with the AIBG group. All clinical parameters improved postoperatively. However, there
was no difference in changes in VAS, ODI, or SF-36 between the groups. No serious adverse event
related to E.BMP-2 was found.
CONCLUSIONS: The fusion rate of E.BMP-2 was comparable with that of AIBG following PLF.
Good clinical efficacy and safety of E.BMP-2 in spinal fusion were also revealed. It was also sug-
gested that HA shows suitability as a carrier for E.BMP-2. Thus, E.BMP-2 with an HA carrier can
be an alternative bone graft material in spinal fusion. © 2017 The Authors. Published by Elsevier
Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Introduction
Posterior lumbar interbody fusion or posterolateral fusion
(PLF) is a frequently used procedure following wide decom-
pression caused by spinal stenosis or spondylolisthesis.
Traditionally, iliac crest bone graft was used to achieve solid
bone fusion in spinal surgery. However, there were several
problems, such as donor-site morbidity and insufficient volume
in cases of osteoporosis or PLF [1]. To avoid the disadvan-
tages of iliac bone graft, various bone graft substitutes,
including local bone, allograft, or demineralized bone matrix,
have been attempted and studied [2,3].
Recently, recombinant human bone morphogenetic protein-2
(rhBMP-2) has been widely researched as a bone graft sub-
stitute, which is known to have an osteoinductive activity [4,5].
Previously, mammalian origin cell lines, such as Chinese
Hamster Ovary cells, were used to purify rhBMP-2 [6].
However, this method incurred low yield and high cost for
obtaining sufficient amounts of rhBMP-2 because of a post-
translational problem [7]. To overcome this problem,
Escherichia coli-derived rhBMP-2 (E.BMP-2) has been re-
searched as an alternative, and comparable efficacy has been
reported [8,9]. Regardless of the economic advantage with
large quantity production, the efficacy of E.BMP-2 has been
questioned because dimerization does not occur in the final
structure. In fact, it was reported that the osteoblastic differ-
entiation by E.BMP-2 in mesenchymal stem cells was inferior
to that in Chinese Hamster Ovary cell rhBMP-2 [10]. However,
it has been reported that the efficacy of both forms of rhBMP-2
showed no difference for in vivo studies [8,11]. Osteoinductivity
of E.BMP-2 has also been reported in many studies [9,11,12].
Furthermore, high purity has been suggested by dimeriza-
tion through biochemical processing [11,13].
Application of rhBMP-2 requires carriers. Previously, a
collagen carrier was frequently used [14]. However, it ex-
hibits poor osteoconductivity and poor affinity for rhBMP2.
Subsequently, calcium phosphate-based ceramics were sug-
gested to overcome these disadvantages [15]. Additionally,
osteoinductive activity by E.BMP-2 with a hydroxyapatite
(HA) carrier was proposed in an animal model [16].
Therefore, we attempted to reveal the efficacy and safety
of E.BMP-2 with an HA carrier when applied to lumbar pos-
terolateral fusion. Although there have been several studies
comparing clinical outcomes and safety profiles between
rhBMP-2 and autogenous iliac bone graft (AIBG) in lumbar
fusion surgery, this is the first study to analyze the efficacy
and safety of E.BMP-2 with an HA carrier compared with
AIBG in spinal fusion. Thus, this study aims to compare clin-
ical efficacy and safety of E.BMP-2 with an HA carrier and
AIBG as bone graft substitutes in lumbar PLF.
Materials and methods
Study design
This study was an open, active-controlled, randomized, mul-
ticenter trial. Patients were enrolled competitively in eight
institutions from March 2013 to March 2016 after approval
from the institutional review board at each institution. This
trial was registered in ClinicalTrials.gov (NCT01764906) and
was conducted following the principles of the Declaration of
Helsinki and guidelines of Good Clinical Practice.
Inclusion criteria were as follows: (1) 18–80 years old and
(2) patients requiring one-level posterior decompression and
L1 and S1 fusion because of severe spinal stenosis, grade 1
spondylolisthesis, or spondylolysis. Exclusion criteria were
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as follows: (1) average spine T-score <−3.0 on dual-energy
X-ray absorptiometry, (2) history of cancer (<5-year disease-
free state is confirmed), (3) serum calcium and phosphorous
level below −30% of the normal lower limit or above 30%
of the normal upper limit, (4) patients who cannot stop an-
ticoagulation therapy, (5) diabetes with serious complications,
(6) female patients in their childbearing years who do not agree
with contraception during the clinical trial period, and (7) spe-
cific conditions including psychological problems, drug
intoxication, liver disease, kidney disease, respiratory disease,
or metabolic disease.
History, vital signs, and informed consent were obtained
during the screening period. Patients were regularly followed
up at 2, 12, and 24 weeks postoperatively. Plain radiographs
were obtained and laboratory tests were conducted at every
visit, and three-dimensional computed tomography (CT, thin
cut, <2 mm) was obtained at 12 and 24 weeks postopera-
tively. Clinical outcomes were evaluated by the visual analogue
scale (VAS) concerning back and leg pain, Oswestry Disabil-
ity Index (ODI), and Short Form-36 (SF-36) Health Survey
preoperatively and 12 and 24 weeks postoperatively.
Randomization
Enrolled patients were randomized to two groups in a 1:1
ratio. Randomization was conducted through an interactive
web response system. To minimize bias, stratified block ran-
domization by each institution was used. Randomized
allocation codes were generated by PROC PLAN proce-
dure using the Statistical Analysis System (SAS Institute Inc,
Cary, NC, USA). Surgeons were blinded until the operation
day, and could not identify randomization codes for pa-
tients in advance.
Intervention
Lumbar PLF was performed as a routine matter. After pos-
terior midline approach, decompression with laminectomy and
flavectomy was performed. Pedicle screw fixation in the in-
volved level and assigned bone graft materials were applied
between two transverse processes. In the E.BMP-2 group, we
used Novosis (Bioalpha Inc, Gyeonggi-do, Korea), which was
E. coli-derived rhBMP-2 with an HA carrier. About 3 g (8 cc)
of HA was soaked with 1 vial (3.0 mg) of E.BMP-2 and
applied in the intertransverse space with caution to avoid
leaking into the neural structure. This process was repeated
in the contralateral side. In the AIBG group, about 8 cc of
iliac bone graft was used in each side. The bone graft from
laminectomy was not used in both groups. Then, wound
closure was performed after applying suction drainage.
Outcome measures
The primary outcome measure was CT-based fusion rate
at 12 and 24 weeks. The fusion status was assessed by bone
bridging in coronal reconstruction images of CT scans. Sec-
ondary outcome measures were fusion grade by radiographs
and CT at 12 and 24 weeks, and percent change from base-
line of ODI, SF-36, and VAS. Fusion grade was defined as
follows: grade 1—no fusion; grade 2—partial or limited uni-
lateral; grade 3—partial or limited bilateral; grade 4—solid
unilateral; grade 5—solid bilateral [17]. Fusion grades 2, 3,
4, and 5 were defined as “fusion.” Radiological outcomes were
assessed twice at a one-month interval by two independent
radiologists who were not involved with any other aspects
of the study.
Percent change from baseline of ODI, SF-36, and VAS was
calculated as (ODI, SF-36, and VAS at each visit − Baseline)/
Baseline × 100 (%). In case of SF-36, mean score was used
in the calculation after converting the score of each item to
a scale of 0–100.
Safety evaluation
Safety of E.BMP-2 was evaluated by occurrence and se-
verity of all adverse events. Treatment-emergent adverse events
were analyzed by each group and each part of the body. Each
event was assessed for a relationship with E.BMP-2.
Statistical analysis
Sample size was estimated using the study of Glassman
et al. [17]. In this study, fusion grades at 24 weeks were
4.35±1.11 and 3.16±1.44 in the rhBMP-2 group and AIBG
group, respectively. In this regard, the limit of non-inferiority
Context
The authors performed an RCT looking at fusion rates and
clinical outcomes between E. coli-derived rhBMP-2 in an
HA carrier and ICBG for single-level instrumented pos-
terolateral fusions.
Contribution
They found no statistically significant differences in fusion
rates, functional and pain outcomes, and complication rates.
Implications
The basic methodology in this study is solid, but caution
is worthwhile. Concerns include the short-term follow-
up (24 weeks); the ability to accurately assess fusion when
HA hasn’t yet resorbed; no mention of costs/value (ICBG
fused and had equal postop pain—so the older argu-
ments for BMPs that included differences in need for
revision and morbidities don’t apply); and financial con-
flicts of interest. Previous studies of rhBMP-2 in
posterolateral fusion have shown increased risk of early
radicular pain and seroma (which were not directly as-
sessed in this study), and the need for high doses to obtain
fusion that likely increase the risk potential.
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was established as 1.1. The null hypothesis was that the in-
feriority of E.BMP-2 to autogenous iliac bone graft, based
on CT-based fusion grade at 24 weeks, would be greater than
the non-inferiority limit (fusion grade in the E.BMP
group − fusion grade in the AIBG group >−1.1). To obtain
a power of 90% with an alpha of 0.05, 40 patients were re-
quired for each group with a 1:1 randomization ratio. Finally,
50 patients were to be enrolled in each group in anticipa-
tion of a 20% follow-up loss.
Demographic data were analyzed descriptively. Compar-
ative analysis between the groups was performed using the
two-sample t test or Wilcoxon rank sum test for continuous
variables and chi-square test or Fischer exact test for cate-
gorical variables. Intraobserver and interobserver agreements
were assessed by calculating intraclass correlation coeffi-
cients (ICCs), with ICCs of 0.8 to 1.0, 0.6–0.79, and <0.6
defined as good, moderate, and poor, respectively. All sta-
tistical analyses were performed using the Statistical Analysis




Among the 103 patients screened, 100 patients were ran-
domized into the two groups. After exclusion (5 withdrawal,
1 violation of the protocol, and 1 incompatibility judged by
the investigator), the intention-to-treat analysis of the out-
comes was based on 93 patients (42 for the BMP-2 group
and 51 for the AIBG group). Enrollment, allocation, and ex-
clusion are summarized in Fig. 1. Per-protocol analysis was
based on 87 patients after excluding a further six patients who
violated the protocols during follow-up. Six violations of pro-
tocols were as follows: 2 absence of 24-week CT scans, and
4 uses of prohibited drugs or therapies.
Demographic and baseline characteristics did not differ
between the E.BMP-2 and AIBG groups (Table 1). Opera-
tion time (168 minutes vs. 180 minutes, p=.148), degree of
transfusion (484 mL vs. 558 mL, p=.376), and hospitaliza-
tion period (10.2 vs. 10.4 days, p=.553) did not differ between
the groups.
Fig. 1. Flow diagram showing the process of enrollment, allocation, follow-up, and analysis.
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Primary outcome measure
CT-based fusion rates showed no difference between the
groups. Fusion rates at 12 weeks were 100.0% (42/42) in the
E.BMP-2 group and 90.2% (46/51) in the AIBG group
(p=.062). Fusion rates at 24 weeks were 100.0% (41/41) in
the E.BMP-2 group and 94.1% (48/51) in the AIBG group
(p=.251).
Characteristics of fusion in CT images were slightly dif-
ferent between the groups. Although fusion mass was detected
in both groups, HA carriers remained without resorption in
the E.BMP-2 group. However, continuity of fused mass was
more uniformly observed in the AIBG group than the E.BMP-2
group (Fig. 2).
Secondary outcome measures and adverse events
Fusion grade based on radiographs and CT at 12 and 24
weeks are compared in Table 2. In all analyses, lower limit
of the 95% confidence interval was greater than the non-
inferiority limit (−1.1). Intraobserver agreements were good
(ICC=0.836 for rater 1 and 0.802 for rater 2). Interobserver
agreements were moderate (ICC=0.785 for the first rating and
0.748 for the second rating). Clinical parameters showed im-
provement postoperatively in both groups. VAS (lumbar, right
leg, and left leg), ODI, and SF-36 at baseline, 12 weeks, and
24 weeks are described in Fig. 3. No differences for each clin-
ical parameter were observed between the groups at baseline,
12 weeks, and 24 weeks. In addition, percent change from
baseline of VAS, ODI, and SF-36 showed no difference at
12 and 24 weeks between the groups (Table 3).
The most frequently observed adverse events were con-
stipation (11 patients in the E.BMP-2 group and 10 patients
in the AIBG group) and pyrexia (9 patients in the E.BMP-2
group and 13 patients in the AIBG group). However, there
was no difference for overall adverse events between the
groups (p=.975). Serious treatment-emergent adverse events
were detected in 9 patients (10 cases): two for the E.BMP-2
group and eight for the AIBG group (Table 4, p=.173).
However, no events were related to the medical device. No
deaths or serious complications leading to trial termination
Table 1





Age (y) 64.9±8.4 62.0±9.2 .121
Gender .533
Male 20 (47.6%) 21 (41.2%)
Female 22 (52.8%) 30 (58.8%)
Height (cm) 160.4±9.2 160.1±9.0 .982
Weight (kg) 64.4±9.6 66.4±10.8 .354
BMI (kg/m2) 25.0±3.1 25.9±3.3 .214
Smoking .345
Current smoker 4 (9.5%) 6 (11.8%)
Ex-smoker 6 (14.3%) 13 (25.5%)
Non-smoker 32 (76.2%) 32 (62.7%)
Drinking 1.000
Current drinker 13 (40.0%) 17 (33.4%)
Ex-drinker 4 (9.5%) 4 (7.8%)
Non-drinker 25 (59.5%) 30 (58.8%)
BMD (T-score) −0.4±1.5 −0.2±1.7 .555
Radiological findings
Grade 1 spondylolisthesis 22 (52.4%) 25 (49.0%)
Spinal stenosis 31 (73.8%) 43 (84.3%)
Spondylolysis 0 2 (3.9%)
Herniated intervertebral disc 7 (16.7%) 14 (27.5%)
E.BMP-2, Escherichia coli-derived recombinant human bone morpho-
genetic protein-2; AIBG, autogenous iliac bone graft; BMI, body mass index;
BMD, bone mineral density.
Table 2





Fusion grade by radiographs
(12 wk)
4.86±0.47 4.20±1.00 <.001
Mean difference (95% CI) 0.66 (0.33, 0.99)
Fusion grade by radiographs
(24 wk)
4.98±0.16 4.04±1.09 <.001
Mean difference (95% CI) 0.93 (0.60, 1.27)
Fusion grade by CT (12 wk) 4.48±0.83 4.02±0.93 .013
Mean difference (95% CI) 0.46 (0.09, 0.82)
Fusion grade by CT (24 wk) 4.56±0.81 3.98±0.94 <.001
Mean difference (95% CI) 0.61 (0.25, 0.97)
E.BMP-2, Escherichia coli-derived recombinant human bone morpho-
genetic protein-2; AIBG, autogenous iliac bone graft; CT, computed
tomography; CI, confidence interval.
}Table 3







VAS (lumbar) at 12 wk −66.4±33.3 −37.8±97.7 .288
Mean difference (95% CI) −28.62 (−59.42, 2.18)
VAS (lumbar) at 24 wk −56.4±37.9 −42.4±88.3 .814
Mean difference (95% CI) −14.08 (−42.91, 14.75)
VAS (left leg) at 12 wk −70.1±43.5 −47.0±106.3 .819
Mean difference (95% CI) −23.08 (−57.78, 11.62)
VAS (left leg) at 24 wk −67.3±40.9 −56.1±77.8 .247
Mean difference (95% CI) −11.17 (−37.92, 15.59)
VAS (right leg) at 12 wk −47.6±124.5 −68.4±46.7 .651
Mean difference (95% CI) 20.75 (−22.72, 64.22)
VAS (right leg) at 24 wk −38.4±142.6 −64.3±81.2 .404
Mean difference (95% CI) 25.83 (−27.46, 79.12)
ODI at 12 wk −29.8±48.7 −36.1±44.8 .480
Mean difference (95% CI) 6.35 (−12.92, 25.62)
ODI at 24 wk −39.1±44.6 −38.3±43.6 .960
Mean difference (95% CI) −0.79 (−19.13, 17.56)
SF-36 at 12 wk 50.2±62.8 50.3±87.1 .881
Mean difference (95% CI) −0.10 (−31.05, 30.86)
SF-36 at 24 wk 60.3±74.3 60.0±87.4 .684
Mean difference (95% CI) 0.29 (−33.82, 34.40)
E.BMP-2, Escherichia coli-derived recombinant human bone morpho-
genetic protein-2; AIBG, autogenous iliac bone graft; VAS, visual analogue
scale; ODI, Oswestry Disability Index; SF-36, Short Form-36 Health Survey;
CI, confidence interval.
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were found. In addition, no difference of laboratory tests was
found between two groups.
Discussion
The efficacy of rhBMP-2 in spinal surgery has been
widely researched. Many studies revealed comparable fusion
rates and clinical outcomes for rhBMP-2 as a bone graft
substitute in different types of spinal fusion. More rapid
incorporation and formation of fusion mass was suggested
when rhBMP-2 was used as a bone graft substitute in PLF
[17]. In another multicenter trial, the fusion rate was higher
in the rhBMP-2 group than in the autograft group (94% vs.
69%, p=.007), although clinical outcomes were not differ-
ent [18]. The efficacy of E.BMP-2 as an alternative to
mammalian cell origin rhBMP-2 was also suggested in animal
studies [19,20]. Additionally, osteoinductivity of E.BMP-2
was comparable with that of mammalian cell BMP-2 [21,22].
Based on our study, efficacy of E.BMP-2 with an HA carrier
in spinal fusion was comparable with that of an autograft.
Moreover, there was a trend of early fusion in the E.BMP-2
group compared with the AIBG group (100.0% vs. 90.2%,
at 3 months), although it did not reach statistical signifi-
cance (p=.062). This difference disappeared 6 months
postoperatively (p=.251). This means that more rapid fusion
might be induced by E.BMP-2. Osteoinductive activity to
induce rapid fusion will be critical for patients with specific




Fig. 2. Characteristics of fusion mass taken in postoperative 12 weeks. (A) Fusion mass in a radiograph in the E.BMP-2 group (arrows). (B) Remaining HA
carrier without resorption in the E.BMP-2 group. (C) Fusion mass in a radiograph in the AIBG group (arrows) (D) Continuously fused mass in the AIBG
group. AIBG, autogenous iliac bone graft; E.BMP-2, Escherichia coli-derived recombinant human bone morphogenetic protein-2; HA, hydroxyapatite.
1871J.H. Cho et al. / The Spine Journal 17 (2017) 1866–1874
increased by a higher dosage of E.BMP-2, which was sup-
ported by previous studies [16,19].
However, the toxicity of E.BMP-2 can be a problem with
higher dosage. No observed adverse effects occurred with the
intravenous administration of 0.5 mg/kg E.BMP-2 in rats [23].
It was also suggested that the lethal dose of E.BMP-2 would
be higher than 7.0 mg/kg in rats [24]. These studies showed
relative safety of E.BMP-2. We used 3 mg of E.BMP-2 bi-
laterally. If we assume that the mean weight of patients is
60 kg, then 0.1 mg/kg is the corresponding dose used herein.
This is thought to be a safe dose based on previous toxicol-
ogy studies. In fact, no E.BMP-2-related complications were
observed during this trial.
Conversely, there have been several reports expressing
concern because of high complication rates. High subsi-
dence rate and end plate resorption were frequently reported,
although their clinical significance was not clearly revealed
[25–29]. Painful seroma formation, which required revision
surgery, was reported in 4.6% of the patients [30]. Soft tissue
swelling can be a life-threatening complication, especially in
cervical anterior surgery [31]. This critical safety issue pre-
vented widespread use of rhBMP-2, especially in the cervical
spine [32,33]. In addition, retrograde ejaculation [34–36], direct
neural toxicity [37,38], and foraminal ossification were sug-
gested by many studies [39].
Nevertheless, there is also support for the safety of rhBMP-2
[40,41]. However, it would be prudent to judge the risk of
complications based on the recent meta-analysis [36]. They
demonstrated a higher rate of general complications as well
as retrograde ejaculation, heterotopic ossification, and cer-
vical tissue swelling. In our study, the incidence of general
complications as well as serious adverse events did not differ
between the groups. Because degrees of improvement in clin-
ical outcomes did not differ between the groups, it was inferred
that the risk of neuritis or symptomatic seroma formation did
not increase. However, because the trial period of this study
was 24 weeks from the surgery, only short-term complica-
tions could be detected. In fact, one of the concerns of using




Fig. 3. Comparison of clinical parameters between the groups. (A) Oswestry Disability Index (ODI), (B) Short Form-36 (SF-36), (C) Visual analogue scale
(VAS) (lumbar), (D) VAS (left leg), (E) VAS (right leg). AIBG, autogenous iliac bone graft; E.BMP-2, Escherichia coli-derived recombinant human bone
morphogenetic protein-2.
Table 4





Overall 2 (4.8%) 8 (15.7%) .107
Pyrexia 1 (2.4%) 1 (2.0%)
Pneumonia 0 1 (2.0%)
Urinary tract infection 0 1 (2.0%)
Postoperative hematoma 0 1 (2.0%)
Wound dehiscence 0 1 (2.0%)
Abdominal pain 1 (2.4%) 0




Deep vein thrombosis 0 1 (2.0%)
E.BMP-2, Escherichia coli-derived recombinant human bone morpho-
genetic protein-2; AIBG, autogenous iliac bone graft.
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resulted from the possible activation of BMP receptors in
various cancer types. However, the risk of developing a new
cancer was not likely to be higher than expected. In one ret-
rospective cohort study of 527 patients, the standardized
incidence ratio for cancer was 0.84 [0.56–1.21] [42]. In ad-
dition, no correlation was reported between the use of rhBMP-2
and development of cancer (hazard ratio=0.99 [0.95–1.02])
in another large-scale retrospective cohort study [43].
The applicability of rhBMP-2 is another important issue.
Stable carriers with high osteoconductive activity and good
affinity for rhBMP-2 are required to enhance the osteoinductive
activity of rhBMP-2. Although collagen carriers were fre-
quently used in the past, HA has been suggested as an
alternative. The HA granules existed in CT images 6 months
postoperatively without resorption, which means stability of
HA as a carrier. Its higher affinity with E.BMP-2 has been
proposed by several studies [20,44]. The suitability of HA
as a carrier for E.BMP-2 was also confirmed in this study.
This study has a few limitations. First, drop-out rate (13%)
due to the violation of the protocol or withdrawal was not
low, even though follow-up loss was absent. This was mainly
caused by the strict regulation protocol. Second, the number
of enrolled patients were not equal among the institutions
because enrollment was conducted in a competitive manner.
However, no differences of outcomes were found among the
institutions. Third, quality of bone fusion was not assessed.
In a previous study, quality of bone fusion by rhBMP-2 was
reported to be inferior to that of AIBG in anterior lumbar
interbody fusion [45]. We did not assess the quality of bone
fusion due to remaining HA granules in the E.BMP-2 group,
while continuous bone fusion mass was obviously found for
the AIBG group in CT images. Fourth, the follow-up period
was not adequate to evaluate long-term clinical outcomes and
safety. Regardless of the above limitations, this prospective
randomized controlled trial is thought to be worthy of notice
based on the solid study design with reliable sample size es-
timation and strict study protocol. However, this is the first
study to compare the efficacy and safety of bone graft sub-
stitutes between E.BMP-2 with an HA carrier and AIBG in
PLF.
In conclusion, the fusion rate with E.BMP-2 was compa-
rable with AIBG following PLF. Good clinical efficacy and
safety of E.BMP-2 in spinal fusion were also revealed in this
study. It was also suggested that HA showed suitability as a
carrier for E.BMP-2. Thus, E.BMP-2 with an HA carrier can
be an alternative bone graft material in spinal fusion.
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